241 related articles for article (PubMed ID: 12186907)
1. Herpes simplex virus type 1 evades the effects of antibody and complement in vivo.
Lubinski JM; Jiang M; Hook L; Chang Y; Sarver C; Mastellos D; Lambris JD; Cohen GH; Eisenberg RJ; Friedman HM
J Virol; 2002 Sep; 76(18):9232-41. PubMed ID: 12186907
[TBL] [Abstract][Full Text] [Related]
2. Immune evasion by herpes simplex virus type 1, strategies for virus survival.
Friedman HM
Trans Am Clin Climatol Assoc; 2003; 114():103-12. PubMed ID: 12813914
[TBL] [Abstract][Full Text] [Related]
3. The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo.
Lubinski JM; Lazear HM; Awasthi S; Wang F; Friedman HM
J Virol; 2011 Apr; 85(7):3239-49. PubMed ID: 21228231
[TBL] [Abstract][Full Text] [Related]
4. Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E.
Hook LM; Huang J; Jiang M; Hodinka R; Friedman HM
J Virol; 2008 Jul; 82(14):6935-41. PubMed ID: 18480440
[TBL] [Abstract][Full Text] [Related]
5. In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor.
Nagashunmugam T; Lubinski J; Wang L; Goldstein LT; Weeks BS; Sundaresan P; Kang EH; Dubin G; Friedman HM
J Virol; 1998 Jul; 72(7):5351-9. PubMed ID: 9620988
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein C of Herpes Simplex Virus 1 Shields Glycoprotein B from Antibody Neutralization.
Komala Sari T; Gianopulos KA; Nicola AV
J Virol; 2020 Feb; 94(5):. PubMed ID: 31826995
[TBL] [Abstract][Full Text] [Related]
7. Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine.
Awasthi S; Lubinski JM; Friedman HM
Vaccine; 2009 Nov; 27(49):6845-53. PubMed ID: 19761834
[TBL] [Abstract][Full Text] [Related]
8. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC.
Lubinski J; Wang L; Mastellos D; Sahu A; Lambris JD; Friedman HM
J Exp Med; 1999 Dec; 190(11):1637-46. PubMed ID: 10587354
[TBL] [Abstract][Full Text] [Related]
9. Herpes simplex virus type 1 glycoprotein E domains involved in virus spread and disease.
Saldanha CE; Lubinski J; Martin C; Nagashunmugam T; Wang L; van Der Keyl H; Tal-Singer R; Friedman HM
J Virol; 2000 Aug; 74(15):6712-9. PubMed ID: 10888608
[TBL] [Abstract][Full Text] [Related]
10. Immunization strategies to block the herpes simplex virus type 1 immunoglobulin G Fc receptor.
Lin X; Lubinski JM; Friedman HM
J Virol; 2004 Mar; 78(5):2562-71. PubMed ID: 14963159
[TBL] [Abstract][Full Text] [Related]
11. Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1.
Friedman HM; Wang L; Pangburn MK; Lambris JD; Lubinski J
J Immunol; 2000 Oct; 165(8):4528-36. PubMed ID: 11035093
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus glycoproteins E and I facilitate cell-to-cell spread in vivo and across junctions of cultured cells.
Dingwell KS; Brunetti CR; Hendricks RL; Tang Q; Tang M; Rainbow AJ; Johnson DC
J Virol; 1994 Feb; 68(2):834-45. PubMed ID: 8289387
[TBL] [Abstract][Full Text] [Related]
13. Immune evasion properties of herpes simplex virus type 1 glycoprotein gC.
Friedman HM; Wang L; Fishman NO; Lambris JD; Eisenberg RJ; Cohen GH; Lubinski J
J Virol; 1996 Jul; 70(7):4253-60. PubMed ID: 8676446
[TBL] [Abstract][Full Text] [Related]
14. Viral interference with antibody and complement.
Lubinski J; Nagashunmugam T; Friedman HM
Semin Cell Dev Biol; 1998 Jun; 9(3):329-37. PubMed ID: 9665870
[TBL] [Abstract][Full Text] [Related]
15. Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody.
Hook LM; Lubinski JM; Jiang M; Pangburn MK; Friedman HM
J Virol; 2006 Apr; 80(8):4038-46. PubMed ID: 16571820
[TBL] [Abstract][Full Text] [Related]
16. Differences in the role of glycoprotein C of HSV-1 and HSV-2 in viral binding may contribute to serotype differences in cell tropism.
Gerber SI; Belval BJ; Herold BC
Virology; 1995 Dec; 214(1):29-39. PubMed ID: 8525631
[TBL] [Abstract][Full Text] [Related]
17. Herpes Simplex Virus 1 Specifically Targets Human CD1d Antigen Presentation To Enhance Its Pathogenicity.
Rao P; Wen X; Lo JH; Kim S; Li X; Chen S; Feng X; Akbari O; Yuan W
J Virol; 2018 Nov; 92(22):. PubMed ID: 30185591
[TBL] [Abstract][Full Text] [Related]
18. Characterization of domains of herpes simplex virus type 1 glycoprotein E involved in Fc binding activity for immunoglobulin G aggregates.
Dubin G; Basu S; Mallory DL; Basu M; Tal-Singer R; Friedman HM
J Virol; 1994 Apr; 68(4):2478-85. PubMed ID: 7511171
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
[TBL] [Abstract][Full Text] [Related]
20. Kinetic analysis of glycoprotein C of herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b.
Rux AH; Lou H; Lambris JD; Friedman HM; Eisenberg RJ; Cohen GH
Virology; 2002 Mar; 294(2):324-32. PubMed ID: 12009874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
